Emerging studies have focused on ways to treat cancers by modulating T cell activation. However, whether B cell receptor signaling in the tumor microenvironment (TME) can be harnessed for immunotherapy is unclear. Here, we report that an Asia-specific variant of human IgG1 containing a Gly396 to Arg396 substitution (hIgG1-G396R) conferred improved survival of patients with colorectal cancer (CRC). Mice with knockin of the murine functional homolog mIgG2c-G400R recapitulated the alleviated tumorigenesis and progression in murine colon carcinoma models. Immune profiling of the TME revealed broad mobilizations of IgG1+ plasma cells, CD8+ T cells, CD103+ DCs, and active tertiary lymphoid structure formation, suggesting an effective antitumor microenvironment in hIgG1-G396R CRC patients. Mechanistically, this variant potentiated tumor-associated antigen–specific (TAA-specific) plasma cell differentiation and thus antibody production. These elevated TAA-specific IgG2c antibodies in turn efficiently boosted the antibody-dependent tumor cell phagocytosis and TAA presentation to effector CD8+ T cells. Notably, adoptive transfer of TAA-specific class-switched memory B cells harboring this variant exhibited therapeutic efficacy in murine tumor models, indicating their clinical potential. All these results prompted a prospective investigation of hIgG1-G396R in patients with CRC as a biomarker for clinical prognosis and demonstrated that manipulating the functionality of IgG1+ memory B cells in tumors could improve immunotherapy outcomes.
Background: Regulatory B cells (Bregs) are a distinct subset of B cells that play a crucial role in regulating immune responses and maintaining immune tolerance in cancerous environments. However, their function in lung adenocarcinoma (LUAD) remains largely underexplored. This study seeks to investigate the roles of Breg-associated genes in the context of LUAD.Methods: ConsensusClusterPlus package was used to characterize LUAD patients into two clusters. Differentially expressed genes between the two clusters were then used to construct the BREGI using 32 algorithms, including traditional regression, machine learning, deep learning, and 274 different combinations. The training set, TCGA-LUAD, along with SNV and CNV data, was obtained from the TCGA database. Seven external validation sets and one single-cell RNA sequencing set were downloaded from GEO. Data from the TIDE, TCIA, and TIGER websites were curated to assess the effectiveness of immunotherapy.Results: LUAD patients were divided into two clusters based on 27 Breg-related genes. Patients in Cluster C1 exhibited better prognosis, along with higher immune cell infiltration and immune molecule expression levels, displaying characteristics of a “hot immune” phenotype. The BREGI demonstrated robust predictive power for LUAD patient prognosis across various cohorts. Patients with high BREGI were associated with poor prognosis, higher gene mutation frequencies, a “cold immune” phenotype, and potential resistance to immunotherapy.Conclusions: Breg-related genes significantly characterize LUAD patients into distinct clusters, and the BREGI demonstrated strong prognostic value, providing new insights for future research on Bregs.
Non-small cell lung cancer (NSCLC) patients frequently develop resistance to immunotherapy, underscoring the need for novel predictive biomarkers and a deeper understanding of the underlying mechanisms. In this study, we integrated bulk and single-cell transcriptomic analyses across 31 datasets to elucidate the immune infiltration features distinguishing immunotherapy responders from non-responders. We identified elevated infiltration of ZNF683 + CD8 + T cells as a crucial subset enriched in responders, with ZNF683 expression serving as a robust indicator of immunotherapy responsiveness. By screening 296 algorithm combinations, a ZNF683 + CD8 + T cell-related Riskscore (ZNFRS) was constructed using the optimal StepCox[forward] + Ridge combination, which demonstrated superior prognostic capability for lung adenocarcinoma patients. High-ZNFRS tumors exhibited a "cold" tumor microenvironment (TME) characterized by reduced immune infiltration, immunotherapy resistance, and enhanced SPP1 signaling. In vivo experiments revealed that anti-SPP1 treatment suppressed tumor growth, restored CD8 + T cell effector function, inhibited M2-like macrophage polarization, and significantly enhanced the efficacy of anti-PD-1 therapy. Our findings highlight ZNF683 as a promising biomarker for immunotherapy response and establish the ZNFRS as a robust prognostic indicator. Furthermore, targeting the SPP1 pathway, identified as a key driver of immunosuppression in high-risk patients, represents a viable strategy to enhance anti-PD-1 therapy efficacy in NSCLC.
The paper by Yideng Jiang et al, `Ligands of Peroxisome Proliferator-activated Receptor Inhibit Homocysteine induced DNA Methylation of Inducible Nitric Oxide Synthase Gene, ABBS, 2007, 39(5): 366–376 published in Acta Biochimica et Biophysica Sinica on May of 2007, which was found the figure 5A was repeated used. To make the article more scientific and readable, the authors ask for help by replacing the figure 5A with the following figure. The detailed correction information is as follows: